H
harddriver
Well-known member
Italian hospital controlled study showed 66% reduction in death rates when HCQ used...............................published 7/29/20
A total of 539 COVID-19 hospitalised patients were included in our cohort in Milan, from February 24 to May 17,2020 of whom 174 died in hospital (day 14 probability of death: 29.5%–95%CI: 25.5–34.0). We divided a subset of our cohort in three groups who started treatment a median of 1 day after admission: those receiving hydroxycholoroquine alone (N = 197), those receiving hydroxycholoroquine + azithromycin (N = 94), and those receiving neither (controls) (N = 92). Of the latter group, 10 started HIV antivirals (boosted-lopinavir or –darunavir), 1 teicoplanin, 12 immunomodulatory drugs or corticosteroids, 23 heparin and 46 remained untreated. The percent of death in the 3 groups was 27%, 23% and 51%. Mechanical ventilation was used in 4.3% of hydoxychloroquine, 14.2% of hydroxycholoroquine + azithromycin and 26.1% of controls. Unweighted and weighted relative hazards of mortality are shown in Table 1. After adjusting for a number of key confounders (see table), the use of hydroxycholoroquine + azithromycin was associated with a 66% reduction in risk of death as compared to controls; the analysis also suggested a larger effectiveness of hydroxychloroquine in patients with less severe COVID-19 disease (PO2/FiO2 > 300, interaction p-value<.0001). Our results are remarkably similar to those shown by Arshad et al.
https://www.ijidonline.com/article/S1201-9712(20)30600-7/fulltext
https://www.ijidonline.com/article/S1201-9712(20)30600-7/fulltext
When I clicked the link to this article it goes to the site but says article does not exist but if you notice the last digits of the link are in black not all in blue as it should be. So this is very suspect to say the least. You need to enter the entire link to see the article. I redid the link again and it still posted incomplete.
The first 30 minutes of this interview is with Harvey Risch Yale University epidemiologist and worth your time to watch in it's entirety.
A total of 539 COVID-19 hospitalised patients were included in our cohort in Milan, from February 24 to May 17,2020 of whom 174 died in hospital (day 14 probability of death: 29.5%–95%CI: 25.5–34.0). We divided a subset of our cohort in three groups who started treatment a median of 1 day after admission: those receiving hydroxycholoroquine alone (N = 197), those receiving hydroxycholoroquine + azithromycin (N = 94), and those receiving neither (controls) (N = 92). Of the latter group, 10 started HIV antivirals (boosted-lopinavir or –darunavir), 1 teicoplanin, 12 immunomodulatory drugs or corticosteroids, 23 heparin and 46 remained untreated. The percent of death in the 3 groups was 27%, 23% and 51%. Mechanical ventilation was used in 4.3% of hydoxychloroquine, 14.2% of hydroxycholoroquine + azithromycin and 26.1% of controls. Unweighted and weighted relative hazards of mortality are shown in Table 1. After adjusting for a number of key confounders (see table), the use of hydroxycholoroquine + azithromycin was associated with a 66% reduction in risk of death as compared to controls; the analysis also suggested a larger effectiveness of hydroxychloroquine in patients with less severe COVID-19 disease (PO2/FiO2 > 300, interaction p-value<.0001). Our results are remarkably similar to those shown by Arshad et al.
https://www.ijidonline.com/article/S1201-9712(20)30600-7/fulltext
https://www.ijidonline.com/article/S1201-9712(20)30600-7/fulltext
When I clicked the link to this article it goes to the site but says article does not exist but if you notice the last digits of the link are in black not all in blue as it should be. So this is very suspect to say the least. You need to enter the entire link to see the article. I redid the link again and it still posted incomplete.
The first 30 minutes of this interview is with Harvey Risch Yale University epidemiologist and worth your time to watch in it's entirety.
